Evaluation of effects of oral nutrition enriched with Eicosapentaenoic acid(EPA) in patients underwent neoadjuvant chemo therapy for head and neck cancer.
Not Applicable
Recruiting
- Conditions
- Head and neck cancer
- Registration Number
- JPRN-UMIN000007844
- Lead Sponsor
- Juntendo University school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.with incurable other cancer 2.with obvious infectious disease 3.Uncontrollable diabetes mellitus 4.oral administration of steroid 5.with cardiac, liver, or renal failure 6.with allergy of milk and soybean 7.pregnant, lactating women or women of childbearing potential 8.with chronic inflammatory disease 9.lack of agreement 10.incidence of cerebral hemorrhage or subarachnoid hemorrhage within 1 month before registration 11.oral administration of EPA before registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method transition of nutritional condition and inflammatory reaction.
- Secondary Outcome Measures
Name Time Method length of hostpitalization adverse event rate of completion for radical therapy survival rate
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Eicosapentaenoic acid (EPA) influences tumor response in head and neck cancer patients undergoing neoadjuvant chemotherapy?
How does oral EPA supplementation compare to standard nutritional support in preserving lean body mass during head and neck cancer neoadjuvant therapy?
What biomarkers are associated with improved outcomes in head and neck cancer patients receiving EPA-enriched oral nutrition alongside chemotherapy?
What adverse events have been reported in clinical trials combining omega-3 fatty acids with platinum-based chemotherapy for head and neck squamous cell carcinoma?
Are there synergistic effects between Eicosapentaenoic acid (EPA) and EGFR inhibitors in neoadjuvant treatment strategies for human papillomavirus-negative head and neck cancer?